Could a Parkinson's drug ease radiation brain damage?

NCT ID NCT07125222

Not yet recruiting Symptom relief Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether Gocovri, an extended-release form of amantadine, can reduce disability and improve cognitive function in adults who have brain damage from radiation therapy. Participants take the drug daily for about 24 weeks, with the dose increasing after the first month. The study measures changes in disability using the Disability Rating Scale and cognition using the Montreal Cognitive Assessment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gocovri (extended-release amantadine)
What this could lead to: If effective, Gocovri could offer a new way to reduce disability and improve thinking in people with brain damage from radiation therapy.
What could go wrong: This is a small, early-phase trial, so results may not hold up in larger studies. The drug may also cause side effects, and not everyone may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENCEPHALOPATHY RADIATION EFFECT

Contacts and locations

Locations

Weill Cornell Medicine

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.